31 completed, 4 terminated, 2 unknown, 1 active not recruiting. 39 Phase 2, 7 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 39 | Completed 31, Terminated 4, Unknown 2, Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 7 | Completed 6, Unknown 1 |
| Phase 3 | 4 | Completed 4 |
Follow Benign Prostatic Hyperplasia: new trials by email Literature Review of Benign Prostatic Hyperplasia trials Research Report on Benign Prostatic Hyperplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RADA16 for Aquablation Day Case PuraStat - Hematuria, Benign Prostatic Hyperplasia | Phase 2 | Completed | NYU Langone Health | 24 | 2026-05-14 | 2026-11-09 |
| Evaluation of the Functional Outcomes After Bilateral, 3D Ultrasound-guided Focal Thermal Ablation of the Prostate Transition Zone, in Patients With Benign Prostatic Hyperplasia-related Obstruction Targeted Microwave Ablation - Benign Prostatic Hyperplasia | Phase 2 | Terminated | Assistance Publique - Hôpitaux de Paris | 8 | 2024-04-24 | 2026-10-01 |
| Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization Merit Medical Embospheres, Radiation Therapy - Prostate Carcinoma, Benign Prostatic Hyperplasia | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 17 | 2022-02-23 | 2026-07-30 |
| The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility Spermotrend - Male Infertility, Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | Catalysis SL | 150 | 2021-06-15 | 2023-03-28 |
| Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia Composite Steep-pulse Treatment Device, Tamsulosin Hydrochloride Capsules - Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | REMD Medical Technology | 160 | 2020-08-20 | 2022-09-07 |
| The Effect of Traditional Chinese Medicine on Benign Prostatic Hyperplasia VGH-BPH1, Placebo (Corn starch pill manufactured to mimic VGH-BPH1) - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | Taipei Veterans General Hospital, Taiwan | 23 | 2019-03-06 | 2020-04-13 |
| Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004), Placebo - Benign Prostatic Hyperplasia | Phase 2 | Terminated | OPKO Health, Inc. | 114 | 2018-02-21 | 2021-09-16 |
| Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter Optilume™ BPH Prostatic DCB Dilation Catheter, Paclitaxel - Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy | Phase 2 | Completed | Urotronic Inc. | 80 | 2017-12-19 | 2025-11-26 |
| Use of a Novel Radiopaque Embolic Agent in Prostatic Artery Embolisation for Symptomatic Benign Prostatic Enlargement DC Lumi Bead, BTG - Benign Prostatic Hyperplasia | Phase 2 | Unknown | University Hospital Southampton NHS Foundation Trust | 23 | 2017-06-02 | 2020-10-22 |
| Effectiveness and Safety of Adipose-derived Regenerative Cells for Reduction of Risk of Bladder Neck Contracture Liposuction, Transurethral bladder neck resection., ADRC - Bladder Neck Obstruction, Bladder Outlet Obstruction | Phase 1 / Phase 2 | Unknown | Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation | 12 | 2016-01-01 | 2016-08-16 |
| Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Udenafil, Placebo - Erectile Dysfunction, Benign Prostatic Hyperplasia | Phase 2 | Withdrawn | Takeda | 2015-09-01 | 2016-03-04 | |
| A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia talaporfin sodium, Saline, Drug Activator 100 J/cm - Benign Prostatic Hyperplasia | Phase 2 | Completed | Light Sciences Oncology | 225 | 2014-11-01 | 2018-08-08 |
| Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia WC3055, Placebo - Benign Prostatic Hyperplasia | Phase 2 | Completed | Warner Chilcott | 796 | 2013-08-01 | 2015-06-29 |
| Prostate Embolization for Benign Prostatic Hyperplasia Prostatic Embolization with Embosphere Micropsheres - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | James B. Spies, MD | 15 | 2013-08-01 | 2019-12-10 |
| Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD), Doxazosin 4 mg every day (QD) - Benign Prostatic Hyperplasia | Phase 2 | Completed | Buddhist Tzu Chi General Hospital | 140 | 2012-08-01 | 2014-07-15 |
| Effectiveness of onaBoNT-A vs Oral Tamsulosin in Men With BPH and LUTS onaBoNT-A + placebo, Tamsulosin + placebo - Benign Prostatic Hyperplasia, Lower Urinary Track Symptoms | Phase 2 | Completed | VA Office of Research and Development | 63 | 2012-06-01 | 2021-10-05 |
| Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) PRX302, Placebo - Benign Prostatic Hyperplasia | Phase 1 / Phase 2 | Completed | Sophiris Bio Corp | 40 | 2011-09-01 | 2013-08-21 |
| Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia botulinum toxin Type A, Normal saline - Benign Prostatic Hyperplasia | Phase 2 | Completed | Allergan | 315 | 2010-08-01 | 2019-05-03 |
| MCS in the Treatment of Lower Urinary Tract Symptoms MCS-2 15 mg/day, MCS-2 30 mg/day, Placebo - Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia | Phase 2 / Phase 3 | Completed | Health Ever Bio-Tech Co., Ltd. | 274 | 2010-07-01 | 2015-03-03 |
| A Study in Men With Benign Prostatic Hyperplasia LY500307, Placebo - Benign Prostatic Hyperplasia | Phase 2 | Terminated | Eli Lilly and Company | 414 | 2010-04-01 | 2019-04-08 |
Showing 20 of 39. Sign in to see all of them.
Prostatic Hyperplasia (39) · Lower Urinary Tract Symptoms (6) · Erectile Dysfunction (1) · Genital Diseases (1) · Hematuria (1) · Infertility, Male (1) · Prostatic Diseases (1) · Prostatic Neoplasms (1) · Prostatitis (1) · Urinary Bladder Neck Obstruction (1)
Genital Diseases, Male (39) · Male Urogenital Diseases (39) · Urogenital Diseases (39) · Genital Diseases (38) · Prostatic Diseases (38) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (6) · Urological Manifestations (6) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Urologic Diseases (2) · Genital Neoplasms, Male (1) · Hemorrhage (1) · Infertility (1) · Mental Disorders (1)
Botulinum Toxins, Type A (5) · Tadalafil (4) · Tamsulosin (3) · PRX302 (2) · Saline Solution (2) · Sodium Chloride (2) · Talaporfin (2) · Celecoxib (1) · Doxazosin (1) · Drug Implants (1) · Dutasteride (1) · Equol (1) · Ethanol (1) · Lipectomy (1) · Paclitaxel (1)
Eli Lilly and Company (5) · Allergan (3) · Light Sciences Oncology (2) · Sophiris Bio Corp (2) · American Medical Systems (1) · Assistance Publique - Hôpitaux de Paris (1) · Ausio Pharmaceuticals, LLC (1) · Bayer (1) · Buddhist Tzu Chi General Hospital (1) · Catalysis SL (1) · Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation (1) · GlaxoSmithKline (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Health Ever Bio-Tech Co., Ltd. (1) · James B. Spies, MD (1)
United States (19) · Canada (6) · France (4) · Germany (4) · South Korea (4) · Australia (3) · Taiwan (3) · Czechia (2) · Greece (2) · Italy (2) · Japan (2) · Russia (2) · United Kingdom (2) · Austria (1) · China (1)
Allan J Pantuck, MD, MS, FACS (1) · Andrey A Pulin, MD, PhD (1) · Andrey Z Vinarov, MD, PhD, Prof (1) · Christopher Kelly, MD (1) · Christopher P Smith, MD (1) · Denis V Butnaru, MD, PhD (1) · Donald Bergner, MD (1) · Hann-Chorng Kuo, M.D. (1) · Herman Ellman, MD (1) · Jill Moland (1)
PMID 21791356, PMID 15126771, PMID 18461049, PMID 18722631, PMID 19409693, PMID 20163842, PMID 23098762, PMID 26299520, PMID 37354260
U01DK060817 (1)